LETTER TO THE EDITOR

Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia

Blood Cancer Journal (2017) 7, e583; doi:10.1038/bcj.2017.62; published online 14 July 2017

Chronic myeloid leukemia (CML) is characterized by the presence of BCR-ABL1 fusion gene. In over 95% of CML patients, the typical BCR-ABL1 transcript subtypes are e13a2 (b2a2), e14a2 (b3a2) or expression of both simultaneously. Other less frequent transcript subtypes, such as e1a2, e2a2, e6a2, e19a2, e1a3, e13a3 and e14a3, have been sporadically reported. Different subtypes of BCR-ABL1 transcripts encode fusion proteins with different sizes that may lead to different disease phenotypes. The e13a2 and e14a2 transcripts encode P210 BCR-ABL1 proteins with slightly different sizes. Patients with the e14a2 transcript have a significantly higher platelet count than those with the e13a2 transcript. Patients with the e19a2 transcript, which encodes P230, often present with prominent neutrophilic maturation or thrombocytosis, whereas patients with the e1a2 transcript, which encodes P190, often present with monocytosis, absence of basophilia and a tendency to progress to lymphoid blast phase (BP). To investigate the significance of the e1a2 transcript subtype, we examined a cohort of 2322 CML patients treated with tyrosine kinase inhibitors (TKIs), and analyzed the frequency, risk of blast transformation, treatment response and outcomes of patients with this transcript subtype.

CML patients that met following selection criteria were included in this study: (1) receiving TKIs as part of frontline therapy; (2) age at diagnosis ≥ 18 years; and (3) subtype of BCR-ABL1 transcripts confirmed by reverse transcription PCR. BP was defined by the presence of ≥ 20% blasts in peripheral blood or bone marrow.

The study group included 1326 men and 996 women with a median age of 48 years (range, 18–88) at diagnosis. The median follow-up time was 109.8 months (range, 0–221.6 months). A total of 2266 (97.6%) patients had the typical transcripts, including e13a2 (n = 920), e14a2 (n = 950) and both e13a2 and e14a2 (n = 396). Forty-one (1.8%) patients had the e1a2 transcript. Other rare transcript subtypes included e14a3 (n = 4), e13a3 (n = 2), e6a2 (n = 1) and others (n = 8). The clinical characteristics of patients with the e1a2 vs typical transcripts are compared in Table 1a. The median age was 59 years at diagnosis of CML in patients with the e1a2 transcript vs 48 years in patients with the typical transcripts (P < 0.001).

Of CML patients with the e1a2 transcript, 16 had BP, 2 had accelerated phase by blast count and 23 had chronic phase at initial diagnosis. Of the 25 patients who did not have BP initially, 10 had a peripheral blood count and differential count prior to treatment available. All 10 patients had relative and absolute monocytosis at initial presentation, with a median percentage of 11.5% (range, 5–36%), and 7 patients had monocytosis over 10%.

Table 1a. Characteristics of patients with e1a2 vs typical transcripts

| Characteristics | e1a2 transcript (N = 41) | Typical transcripts (N = 2266) | P-value |
|-----------------|-------------------------|-------------------------------|---------|
| Sex             |                         |                               |         |
| Male            | 21                      | 1293                          | 0.45    |
| Female          | 20                      | 973                           |         |
| Age at Dx       |                         |                               |         |
| Median          | 59                      | 48                            | < 0.001 |
| Range           | 18-86                   | 18-88                         |         |
| Blast immunophenotype |                 |                               |         |
| Myeloid         | 8                       | 275                           | < 0.001 |
| Lymphoid        | 13                      | 114                           |         |
| Mixed phenotype | 4                       | 10                            |         |
| Stage at Dx     |                         |                               |         |
| BP              | 16                      | 78                            | < 0.001 |
| Not BP          | 25                      | 2188                          |         |
| ACA at Dx       |                         |                               |         |
| No ACA          | 28                      | 1915                          | 0.003   |
| Single ACA      | 7                       | 126                           |         |
| Multiple ACA    | 2                       | 51                            |         |
| Best response   |                         |                               |         |
| CCyR and above  | 8 (33.3%)               | 1430 (66.5%)                  | < 0.001 |
| MMR and above   | 5 (18.5%)               | 1266 (63.7%)                  | < 0.001 |
| Survival (in months) |                 |                               |         |
| Median OS       | 69.5                    | 206.8                         | < 0.001 |
| Median TFS      | 107.8                   | 202.9                         | 0.006   |
| Status at last F/U |                     |                               |         |
| Dead            | 20                      | 623                           | 0.003   |
| Alive           | 21                      | 1643                          |         |
| Treatment       |                         |                               |         |
| Imatinib        | 36                      | 1722                          | 0.078   |
| Non imatinib    | 5                       | 544                           |         |
| Dasatinib       | 4                       | 271                           |         |
| Nilotinib       | 1                       | 210                           |         |
| Bosutinib       | 0                       | 10                            |         |
| Ponatinib       | 0                       | 53                            |         |
| HSCT            | 7                       | 249                           | 0.219   |

Abbreviations: ACA, additional cytogenetic abnormality; BP, blast phase; CCyR, complete cytogenetic response; Dx, diagnosis; F/U, follow-up; HSCT, hematopoietic stem cell transplantation; MMR, major molecular response; OS, overall survival; TFS, transformation-free survival. *In 4 patients with e1a2 transcript and 174 patients with typical transcripts, the time of ACA emergence was unclear. Patients who were in BP initially were not included in response evaluation; response achieved after blast transformation was not included. Patients who were in BP initially were not included in calculation of TFS.
Patients with the e1a2 transcript had a higher frequency of additional chromosomal abnormalities (ACAs) than those with the typical transcripts: 46.3% (19/41) vs 25.2% (572/2266), $P = 0.002$. Of these with known emerging time of ACAs, 9/37 (24.3%) vs 177/2092 (8.5%) patients with the e1a2 and typical transcripts had ACAs at diagnosis, respectively ($P < 0.001$), and 6/37 (16.2%) vs 221/2092 (10.6%) acquired ACAs during therapy respectively ($P = 0.27$). There was no significant difference in the frequency of
high-risk ACAs, including 3q26.2 rearrangement, −7/7q− and i(17q) (P = 0.33), or complex ACAs between those with the e1a2 and those with the typical transcripts (P = 0.13).

CML patients with the e1a2 transcript had a significantly worse overall survival (OS) than patients with the typical transcripts with a median OS of 69.5 vs 206.8 months, respectively (Figure 1a1, P < 0.001). After excluding patients who had BP initially or ACAs initially and those with unknown emerging time of ACAs, the e1a2 transcript subtype remained an adverse prognostic factor (Figure 1a2).

Patients with the e1a2 transcript were more likely to develop BP than patients with the typical transcripts: 25/41 (61.0%) vs 399/2266 (17.6%), respectively (P < 0.001). When stratified by the timing of BP, 16/41 (39.0%) vs 78/2266 (3.4%) patients with the e1a2 vs typical transcripts developed BP at initial diagnosis, respectively (P < 0.001). In patients who did not present in BP initially, 9/25 (36.0%) vs 321/2188 (14.7%) patients with the e1a2 vs typical transcripts developed BP, respectively, after a median follow-up of 90.3 months (P < 0.001). The hazard ratio for the e1a2 transcript to increase the risk of progression to BP was 2.45 (95% confidence interval: 1.44–4.18). Furthermore, the lineage of BP in patients with the e1a2 transcript was more likely to be lymphoid or mixed phenotype: 17/25 (68.0%) vs 124/399 (31.1%) in those with the typical transcripts (P < 0.001).

In patients who did not present in BP initially, those with the e1a2 transcript had a shorter latency from initial diagnosis to blastic transformation (Figure 1b1). The cumulative probability of blastic transformation at 18 months was 29.2% vs 6.4% in patients with the e1a2 vs typical transcripts, respectively (P < 0.001). After excluding patients with ACAs initially and those with unknown emerging time of ACAs, the e1a2 transcript remained associated with a faster progression to BP (cumulative probability of BP at 18 months: 21.1% vs 61.1%, P = 0.018, Figure 1b2). The significant difference in the latency of blastic transformation in these two groups translated into a significant difference in transformation-free survival (TFS) with a median 107.8 vs 202.9 months (P = 0.006), respectively, when patients with ACAs initially and those with unknown emerging time of ACAs were included (Figure 1c1), and 107.8 vs 206.8 months (P = 0.033), respectively, when patients with ACAs initially and those with unknown emerging time of ACAs were excluded (Figure 1c2).

In multivariate analyses with covariates including sex, age group, disease stage at diagnosis, ACAs prior to blastic transformation and transcript subtypes, the e1a2 transcript subtype independently predicted both a poorer OS (hazard ratio 2.09, P = 0.002) and TFS (hazard ratio 2.05, P = 0.014) (Table 1b).

We then investigated the impact of the e1a2 transcript on treatment responses. Patients with the e1a2 transcript were both significantly slower and less likely to achieve complete cytogenetic remission (CCyR) than those with the typical transcripts, with a median time to CCyR of 53.1 vs 18.8 months, respectively (Figure 1d1, P = 0.003). The overall CCyR rate was 33.3% (8/24) vs 66.5% (1430/2150) in patients with the e1a2 vs typical transcripts, respectively, after a median follow-up time of 53.0 months. When patients with BP initially or ACAs initially and those with unknown emerging time of ACAs were excluded, the difference in CCyR between two groups remained significant (Figure 1d2, median time to CCyR 17.9 vs 53.1 months, P = 0.005).

Patients with the e1a2 transcript were both significantly slower and less likely to achieve major molecular remission (MMR) than those with the typical transcripts, with a median time to MMR unreached vs 31.7 months, respectively (Figure 1e1, P = 0.001). The overall MMR rate was 18.5% (5/24) vs 63.7% (1266/1986) in patients with the e1a2 vs typical transcripts, respectively, after a median follow-up time of 59.5 months. When patients with BP initially or ACAs initially and those with unknown emerging time of ACAs were excluded, the difference in MMR between two groups remained significant (Figure 1e2, P = 0.001).

Here we investigated the impact of the e1a2 transcript subtype in a cohort of 2322 CML patients treated with TKIs. We found that the e1a2 transcript is rare in CML, ~1.8% in this study. Patients with the e1a2 transcript are diagnosed at an older median age, more likely have monocytosis in chronic phase, and more likely to present in BP initially. Those who do not present in BP initially have a higher risk of subsequent progression to BP, an inferior cytogenetic and molecular response to TKI therapy, and an adverse OS and TFS. In multivariate analysis, the e1a2 transcript subtype independently predicts inferior OS and TFS.

Table 1b. Multivariate analysis of prognostic parameters in CML

|                    | OS       | TFS       |
|--------------------|----------|-----------|
|                    | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age group          |          |          |
| < 40               | 1.703 (1.505–1.926) | < 0.001 | 1.484 (1.315–1.675) | < 0.001 |
| 40–64              | 1.311 (1.117–1.538) | 0.001  | 1.267 (1.083–1.483) | 0.003  |
| > 65               | 4.191 (3.066–5.730) | < 0.001 | NA           | NA     |
| Male sex           |          |          |
| Male               | 1.637 (1.275–2.101) | < 0.001 | 1.807 (1.395–2.342) | < 0.001 |
| Female             | 2.091 (1.319–3.314) | 0.002  | 2.046 (1.154–3.630) | 0.014  |
| Initially in BP    |          |          |
| Yes                | 1.000    |          | 1.000    |          |
| No                 | 1.000    |          | 1.000    |          |
| ACAs               |          |          |
| Yes                | 1.000    |          | 1.000    |          |
| No                 | 1.000    |          | 1.000    |          |
| e1a2 transcript    |          |          |
| Yes                | 1.000    |          | 1.000    |          |
| No                 | 1.000    |          | 1.000    |          |

Abbreviations: ACA, additional cytogenetic abnormality; BP, blast phase; CI, confidence interval; CML, chronic myeloid leukemia; HR, hazard ratio; NA, not applicable; OS, overall survival; TFS, transformation-free survival. Age group: < 40, 41–64, > 65.

Figure 1. Impact of e1a2 transcript subtype in CML. (a1) OS of CML patients with e1a2 vs typical transcripts in the entire cohort. (a2) OS of CML patients with e1a2 vs typical transcripts after excluding those with BP initially or ACAs initially and those with unknown emerging time of ACAs. (b1, b2) Time course of blastic transformation in CML patients with e1a2 vs typical transcripts before (b1) and after (b2) excluding those with BP initially or ACAs initially and those with unknown emerging time of ACAs. (c1, c2) TFS in CML patients with e1a2 vs typical transcripts before (c1) and after (c2) excluding those with BP initially or ACAs initially and those with unknown emerging time of ACAs. (d1, d2) CCyR in CML patients with e1a2 vs typical transcripts before (d1) and after (d2) excluding those with BP initially or ACAs initially and those with unknown emerging time of ACAs. A total of 2172 patients had available cytogenetic response data, including 2148 patients with the typical transcripts and 24 patients with the e1a2 transcript. (e1, e2) MMR in CML patients with e1a2 vs typical transcripts before (e1) and after (e2) excluding those with BP initially or ACAs initially and those with unknown emerging time of ACAs. A total of 2010 patients had available molecular response data, including 1986 with the typical transcripts and 24 with the e1a2 transcript.

Blood Cancer Journal
A rapidly growing list of parameters is included as criteria for defining accelerated phase of CML in the 2016 revision to the World Health Organization classification of myeloid neoplasms. These parameters include clinical findings (counts of white blood cells, basophils, platelets and blasts, and splenomegaly), cytogenetic data (such as major-route ACAs at diagnosis and any ACAs acquired during therapy) and response criteria (such as ABL1 mutation). It has been shown that the impact of most of the clinical parameters listed above has been minimized in TKI era. Similarly, although implicated in disease progression and poor outcome of CML patients, not all major-route ACAs or ABL1 mutations detected at diagnosis or acquired during therapy are equally prognostically significant in TKI era. The data in this study indicate that the e1a2 transcript subtype emerges as a new high-risk factor for disease progression. It may be helpful to include e1a2 transcript subtype among the ever-changing list of criteria for accelerated phase in a future classification scheme of CML.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
The study was performed in accordance with the Declaration of Helsinki and approved by the Institutional Review Board at the University of Texas MD Anderson Cancer Center.

REFERENCES
1. Burmeister T, Reinhardt R. A multiplex PCR for improved detection of typical and atypical BCR−ABL1 fusion transcripts. Leuk Res 2008; 32: 579–585.
2. Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Shamanna RK et al. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood 2016; 127: 1269–1275.
3. Perego RA, Costantini M, Cornacchini G, Gargantini L, Bianchi C, Pungolino E et al. The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. Eur J Cancer 2000; 36: 1395–1401.
4. Hanfein B, Lauseker M, Hehlmann R, Saussele S, Erpen P, Dietz C et al. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica 2014; 99: 1441–1447.
5. Hur M, Song E, Kang S-H, Shin D-H, Kim J, Park S et al. Lymphoid preponderance and the absence of basophilia and splenomegaly are frequent in m-bcr-positive chronic myelogenous leukemia. Ann Hematol 2002; 81: 219–223.
6. Ohsaka A, Shina S, Kobayashi M, Kudo H, Kagawuchi R. Philadelphia chromosome-positive chronic myeloid leukemia expressing p190(BCR-ABL). Intern Med 2002; 41: 1183–1187.
7. Ohtake S. Chronic myelogenous leukemia with p190BCR-ABL expression: the missing link with monocytosis. Intern Med 2002; 41: 1092–1093.
8. Arun AK, Senthilnathivel A, Mani S, Vinodhini K, Janet NB, Lakshmi KM et al. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients. Int J Lab Hematol 2016; 39: 235–242.
9. Catania G, Monaco F, Pini M, Corsetti MT, Salvio M, Trinchieri N et al. Prognostic impact of p190 and p210 co-expression at diagnosis in chronic myeloid leukemia (CML) patients treated with Imatinib. Blood 2014; 124: 5528.
10. Arber DA, Orsaz A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391–2405.
11. Kantarjian H, O’Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012; 119: 1981–1987.
12. Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood 2016; 127: 2742–2750.
13. Quintás-Cardama A, Kantarjian H, Shan J, Jabbour E, Abuzzo LV, Verstovsek S et al. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Cancer 2011; 117: 5085–5093.
14. Castagnetti F, Testoni N, Luatti S, Marzocchi G, Mancini M, Kerim S et al. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with Imatinib mesylate: GIMEMA CML Working Party Analysis. J Clin Oncol 2010; 28: 2748–2754.
15. Wang W, Chen Z, Hu Z, Yin C, Li S, Bai S et al. Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia. Blood Cancer J 2016; 6: e490.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017